Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Andrew M Evens, Angie Mae Rodday, Matthew J. Maurer, Ranjana H. Advani, Marc Andre, Andrea Gallamini, Annette E. Hay, David Hodgson, Richard T. Hoppe, Martin Hutchings, Peter Johnson, Brian K. Link, Stephen Opat, John M. Raemaekers, Jenica Upshaw, Qingyan Xiang, Nicholas Counsell, Susan K Parsons, John Radford

Blood (2023) 142 (Supplement 1): 3058.

https://doi.org/10.1182/blood-2023-173320

Published: 2023

Journal Articles

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Michael J. Kelly, MD MPH, MS, Susan K Parsons, MDMRP, David C. Hodgson, MD, Joshua T Cohen, PhD, Jennifer M Yeh, MD PhD, Jeremy S. Abramson, MD, Debra L. Friedman, MD MS, Tara O Henderson, MDMPH, Peter W Johnson, MD, Stephen G Pauker, MD, John M. Raemaekers, MD PhD, Jane N. Winter, MD, Kara M. Kelly, MD, Ralph M. Meyer, MD, Sharon M Castellino, MD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 2635.

https://doi.org/10.1182/blood.V126.23.2635.2635

Published: 2015

Journal Articles

Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG)

Stephanie Sasse, MD, Magdalena Alram, Medical Student, Horst Mueller, PhD, Lenka Smardova, MD, Bernd Metzner, Hartmut Döhner, MD, Thomas Fischer, MD, Vladan Vucinic, Norbert Schmitz, MD, Kerstin Schäfer-Eckart, John M. Raemaekers, MD, PhD, Oliver Schmalz, MD, Bastian von Tresckow, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2012) 120 (21): 552.

https://doi.org/10.1182/blood.V120.21.552.552

Published: 2012

Journal Articles

First Report On the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin's Lymphoma, for the Groupe d'Etude Des Lymphomes De l'Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL).

Marc PE André, MD, Oumédaly Reman, MD, Massimo Fédérico, MD, Pauline Brice, MD, Ercole Brusamolino, MD, Théodore Girinski, MD, Christophe Ferme, MD, Richard vander Maazen, MD, Monica Bellei, Catherine Sebban, MD, Franck Morschhauser, MD, PhD, Elly Lugtenburg, MD, Aspasia Stamatoullas, MD, Liliana Baila, MD, MSc, Catherine Fortpied, MSc, Michel Meignan, MD, John M. Raemaekers, MD, PhD

Blood (2009) 114 (22): 97.

https://doi.org/10.1182/blood.V114.22.97.97

Published: 2009

Journal Articles

Gem-(R)CHOP Versus (R)CHOP: A Randomized Phase II Study of Gemcitabine Combined with (R)CHOP in Untreated Aggressive Non- Hodgkin’s Lymphoma - EORTC Lymphoma Group Protocol 20021

Igor Aurer, Houchingue Eghbali, John M. Raemaekers, Hussein M Khaled, Martine Van Glabbeke, Liliana Baila, Richard van der Maazen

Blood (2008) 112 (11): 3609.

https://doi.org/10.1182/blood.V112.11.3609.3609

Published: 2008

Journal Articles

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

Houchingue Eghbali, MD, Pauline Brice, MD, Geert-Yan Creemers, MD, Marinus van Marwijk Kooij, MD, Patrice Carde, MD, Mars B. Van’t Veer, MD, Elli Lugtenburg, MD, Anne Sonet, MD, Catherine Sebban, MD, Michel Blanc, MD, John M. Raemaekers, MD, Laurent Voillat, MD, Chantal Rieux, Ed M. Noordijk, MD, Michel Henry-Amar, MD

Blood (2005) 106 (11): 814.

https://doi.org/10.1182/blood.V106.11.814.814

Published: 2005

Journal Articles

Intra-Follicular Proliferation Rate Is a Powerful Independent Prognosticator in Follicular Lymphoma.

Ad Koster, Hedwig A. Tromp, John M. Raemaekers, George F. Borm, Marius A. MacKenzie, Joannes H.J.M. Van Krieken

Blood (2004) 104 (11): 4571.

https://doi.org/10.1182/blood.V104.11.4571.4571

Published: 2004

NARROW

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG)

Gem-(R)CHOP Versus (R)CHOP: A Randomized Phase II Study of Gemcitabine Combined with (R)CHOP in Untreated Aggressive Non- Hodgkin’s Lymphoma - EORTC Lymphoma Group Protocol 20021

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

Intra-Follicular Proliferation Rate Is a Powerful Independent Prognosticator in Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG)

Gem-(R)CHOP Versus (R)CHOP: A Randomized Phase II Study of Gemcitabine Combined with (R)CHOP in Untreated Aggressive Non- Hodgkin’s Lymphoma - EORTC Lymphoma Group Protocol 20021

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

Intra-Follicular Proliferation Rate Is a Powerful Independent Prognosticator in Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only